참고문헌
- Arriagada R, Bergman B, Dunant A, et al (2004). Cisplatin_based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med, 350, 351-60. https://doi.org/10.1056/NEJMoa031644
- Alberto ME, Lucas MF, Pavelka M, et al (2009). The secondgeneration anticancer drug Nedaplatin, atheoretical investigation on the hydrolysis mechanism. J Phys Chen B, 113, 14473-9. https://doi.org/10.1021/jp9056835
- Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years, analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
- Hotta K, Matsuo K, Ueoka H, et al (2004). Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplain in patients with advanced non-small-cell lung cancer. J Clin Oncol, 22, 3852-9. https://doi.org/10.1200/JCO.2004.02.109
- Jemal A, Siegel R, Ward E, et al (2008). Cancer statistis, 2008. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
- Jin-ji Yang, Qing Zhou, Ri-qiang Liao, et al (2012). Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer, A Randomized Clinical Trial. Chin J Cancer Res, 24, 97-102. https://doi.org/10.1007/s11670-012-0097-8
- Kameyama Y, Okazaki N, Nakagawa M, et al (1990). Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett, 52, 15-24. https://doi.org/10.1016/0378-4274(90)90161-E
- Kim JL, Cho KH, Park EC, et al (2014). A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev, 15, 433-9. https://doi.org/10.7314/APJCP.2014.15.1.433
- Liu J, Li N, Chang S, et al (2013). Characteristics of 240 Chinese father-child pairs with malignant disease. Asian Pac J Cancer Prev, 14, 6501-5. https://doi.org/10.7314/APJCP.2013.14.11.6501
- Maione P, Rossi A, Bareschino MA, et al (2011). Factors driving the choice of the best second-line treatment of advanced NSCLC. Rev Recent Clin Trials, 6, 44-51. https://doi.org/10.2174/157488711793980192
- Mandal SK, Singh TT, Sharma TD, et al (2013). Clinicopathology of lung cancer in a regional cancer center in Northeastern India. Asian Pac J Cancer Prev, 14, 7277-81. https://doi.org/10.7314/APJCP.2013.14.12.7277
- Niioka Z Uno Z Yasui-Furukori N, et al (2007). Pharmacokinetics of lowdose nedaplatin and validation of AUC prediction in patients with non-small cell lung carcinoma. Cancer Chemother Pharmacol, 59, 575-80. https://doi.org/10.1007/s00280-006-0298-2
- Oven Ustaalioglu BB, Unal OU, Turan N, et al (2013). Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer, multicenter experiences. Asian Pac J Cancer Prev, 14, 6287-92. https://doi.org/10.7314/APJCP.2013.14.11.6287
- Rinaldi M, Cauchi C, Gridelli C, et al (2006). First line chemotherapy in advanced or metastatic NSCLC. Ann OncoL, 17, V64-7. https://doi.org/10.1093/annonc/mdj953
- Sugiyama T, Hirose T, Nakashima M (2011). Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small cell lung cancer. Oncology, 81, 273-80. https://doi.org/10.1159/000334430
- Scagliotti GV, Parikh P'yon Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. https://doi.org/10.1200/JCO.2007.15.0375
- Terret C, Albrand G, Moncenix G, et al (2011). Karnofsky Performance Scale (KPS) or Physical Performance Test (PPD? That is the question. Crit Rev Oncol Hematol, 77, 142-7. https://doi.org/10.1016/j.critrevonc.2010.01.015
- Teramoto K, AsadaY, Ozaki Y, et al (2012). A phase II study of docetaxel plus nedaplatin in patients with metastatic nonsmall-cell lung cancer. Cancer Chemother Pharmacol, 70, 531-7. https://doi.org/10.1007/s00280-012-1941-8
- Wagner TD, Yang GY (2010). The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). Curt Drug Targets, 1l, 67-73. https://doi.org/10.2174/138945010790030956
- Wagner TD, Yang GY (2006). The role of chemotherapy and radiation in the treatment of Belvedere O, Grossi F. Lung Cancer Highlights from ASCO 2005. Oncologist, 11, 39-50. https://doi.org/10.1634/theoncologist.11-1-39
- Yu DP, Han Y, Zhao QY, et al (2012). Pulmonary lobectomy combined with pulmonary arterioplasty by complete videoassisted thoracic surgery in patients with lung cancer. Asian Pac J Cancer Prev, 14, 6061-4. https://doi.org/10.7314/APJCP.2013.14.10.6061
피인용 문헌
- Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
- Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells vol.10, pp.4, 2015, https://doi.org/10.1371/journal.pone.0124994
- Gemcitabine Plus Nedaplatin as Salvage Therapy is a Favorable Option for Patients with Progressive Metastatic Urothelial Carcinoma After Two Lines of Chemotherapy vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2483
- Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells vol.11, pp.4, 2016, https://doi.org/10.3892/ol.2016.4276